A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (LIBRETTO-321)
The reason for this study is to see if the study drug selpercatinib is safe and effective in participants in China with rearranged during transfection (RET) fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 75 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Actual Study Start Date: March 16, 2020
Actual Primary Completion Date: March 25, 2021
Estimated Study Completion Date: April 30, 2023
Arm:
- Experimental: Selpercatinib
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 75 |
| Actual Study start date | 16 March 2020 |
| Estimated Study Completion Date | 30 April 2023 |